scholarly journals Critical cysteine residues for regulation of integrin alphaIIbbeta3 are clustered in the epidermal growth factor domains of the beta3 subunit

2004 ◽  
Vol 378 (3) ◽  
pp. 1079-1082 ◽  
Author(s):  
Tetsuji KAMATA ◽  
Hironobu AMBO ◽  
Wilma PUZON-McLAUGHLIN ◽  
Kenneth Khiem TIEU ◽  
Makoto HANDA ◽  
...  

Chemical or enzymic reduction/oxidation of integrin cysteine residues (e.g. by reducing agents and protein disulphide isomerase) may be a mechanism for regulating integrin function. It has also been proposed that unique cysteine residues in the integrin β3 subunit are involved in the regulation of αIIbβ3. In the present study, we studied systematically the role of disulphide bonds in β3 on the ligand-binding function of αIIbβ3 by mutating individual cysteine residues of β3 to serine. We found that the disulphide bonds that are critical for αIIbβ3 regulation are clustered within the EGF (epidermal growth factor) domains. Interestingly, disrupting only a single disulphide bond in the EGF domains was enough to activate αIIbβ3 fully. In contrast, only two (of 13) disulphide bonds tested outside the EGF domains activated αIIbβ3. These results suggest that the disulphide bonds in the EGF domains should be intact to keep αIIbβ3 in an inactive state, and that there is no unique cysteine residue in the EGF domain critical for regulating the receptor. The cysteine residues in the EGF domains are potential targets for chemical or enzymic reduction.

2004 ◽  
Vol 18 (8) ◽  
pp. 2035-2048 ◽  
Author(s):  
Bukhtiar H. Shah ◽  
Akin Yesilkaya ◽  
J. Alberto Olivares-Reyes ◽  
Hung-Dar Chen ◽  
László Hunyady ◽  
...  

Digestion ◽  
1988 ◽  
Vol 41 (3) ◽  
pp. 121-128 ◽  
Author(s):  
S.J. Konturek ◽  
T. Brzozowski ◽  
A. Dembinski ◽  
Z. Warzecha ◽  
P.K. Konturek ◽  
...  

Oncogene ◽  
2006 ◽  
Vol 26 (23) ◽  
pp. 3431-3439 ◽  
Author(s):  
F Y Feng ◽  
S Varambally ◽  
S A Tomlins ◽  
P Y Chun ◽  
C A Lopez ◽  
...  

2021 ◽  
pp. 62-63
Author(s):  
R. Rani Suganya ◽  
M. Annapoorani ◽  
C. Naveen Kumar

Diabetes mellitus is a disease of large magnitude with 25 million people affected by the disease in India. One of the common complications of this disease is Diabetic foot disease characterised by non-healing ulcers over the foot predominantly. This study is aimed at evaluating the efcacy and tolerability of Recombinant Epidermal Growth Factor treatment in increasing the rate of healing of ulcers and decreasing the duration of ulcer healing among patients with diabetic foot disease thereby improving the quality of life, preventing further morbidity and mortality and shortening hospital stay.


Sign in / Sign up

Export Citation Format

Share Document